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Abstract
Background and Objective
The objective of this study was to determine whether family members of patients with pediatric
multiple sclerosis (MS) have an increased prevalence of autoimmune conditions compared
with controls.
Methods
Data collected during a pediatric MS case-control study of risk factors included information
about various autoimmune diseases in family members. The frequency of these disorders was
compared between cases and controls.
Results
There was an increased rate of autoimmune diseases among family members of pediatric MS cases
compared with controls with ﬁrst-degree history of MS excluded (OR = 2.27, 95% CI 1.71–3.01, p
< 0.001). There was an increased rate of MS among second-degree relatives of pediatric MS cases
compared with controls (OR = 3.47, 95% CI 1.36–8.86, p = 0.009). The OR for MS was 2.64 when
restricted to maternal relatives and 6.37 when restricted to paternal relatives.
Discussion
The increased rates of autoimmune disorders, including thyroid disorders and MS among families
of patients with pediatric MS, suggest shared genetic factors among families with children diagnosed
with pediatric MS.
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Glossary
MS = multiple sclerosis.

Multiple sclerosis (MS) is an autoimmune disorder targeting
the CNS that is most commonly diagnosed in women around
age 30 years.1 An estimated 5% of all MS cases have onset
under age 18 years.2 Multiple genetic and environmental risks
have been identiﬁed for MS.1 Studying pediatric MS provides
a unique opportunity to gain insights into the pathophysiology and causes of MS because of the relatively fewer number
of irrelevant exposures preceding disease onset and the possibility that larger exposures result in earlier onset.
Genetic risk factors for pediatric MS have been reported that
overlap with adult MS. These include HLA-DRB1*15:01 and
multiple class III risk variants.3 Several risk factors for autoimmune disorders, including genetic variants or vitamin D deﬁciency, are shared among various conditions, including MS.4-10
There have been conﬂicting reports about rates of autoimmune
diseases in families of patients with adult MS.11,12 Data consistently, however, note that MS risk is increased among ﬁrstdegree relatives of patients with MS, including children of
parents with MS.13 This study sought to understand the incidence of a history of autoimmune diseases in family members
of pediatric MS cases compared with pediatric controls.

Methods
Participants of this case-control study included children with
MS or clinically isolated syndrome and healthy pediatric subjects recruited at 17 clinics participating as part of a nationwide
study of environmental risk factors in pediatric MS between
November 1, 2011, and July 1, 2017 (R01NS071463, PI
Waubant). Diagnosis and control status was established by the
treating neurologist and conﬁrmed by adherence to published
criteria for pediatric demyelinating disease as determined by a
panel of 3 pediatric MS specialists using the 2010 McDonald
Criteria. Centers obtained institutional review board approval as
well as written informed consent from parents of pediatric
participants and assent as appropriate from children. Criteria
mandated that cases were enrolled within 4 years of symptom
onset. Healthy controls were recruited from primary care, urgent care, or other pediatric clinics at the participating institutions. Eligibility criteria for controls required (1) absence of any
ongoing autoimmune disease (apart from eczema and asthma)
and (2) no history of MS in any immediate, biological family
member. Demographic data including race and ethnicity, consistent with NIH guidelines, were provided by parents of pediatric participants. Standardized medical history questionnaires
were completed by patients and families including family autoimmune disease history.
All analyses were conducted using SAS 9.4 (SAS Institute;
Cary, NC). Patient characteristics were summarized using
2

medians and quartiles or counts and percentages as appropriate. Chi-squared tests were used to compare reported
family history of autoimmune disease between cases and
controls, for both overall history of any disease and for speciﬁc
diseases (e.g., MS).
Logistic regression models were used to test for diﬀerences
between cases and controls in reporting a family history of
autoimmune diseases, when adjusting for sex, race, age, ethnicity, and mother’s education level. ORs and 95% CIs were
calculated based on the logistic regression models.
The diseases that were found to be signiﬁcant in the overall
tests were investigated within 5 relative groups: ﬁrst-degree
relatives, second-degree relatives, parents, maternal relatives,

Table 1 Subject Characteristics
Subject status as case or
control
Control
(N = 709)
Age at enrollment:
median (Q1, Q3)

Case
(N = 495)

15.6 (12.5, 17.8) 16.0 (14.2, 17.5)

0.196b
0.052a

Sex
Male

290 (40.9%)

175 (35.4%)

Female

419 (59.1%)

320 (64.6%)
0.115a

Race
White

438 (61.8%)

311 (62.8%)

Black

107 (15.1%)

87 (17.6%)

Other

114 (16.1%)

60 (12.1%)

Unknown

50 (7.1%)

37 (7.5%)
<0.001a

Ethnicity
Hispanic or Latino

155 (21.9%)

150 (30.3%)

Not Hispanic or Latino

519 (73.2%)

318 (64.2%)

Unknown

35 (4.9%)

27 (5.5%)
<0.001a

Mother’s education level
None

p Value

40 (5.6%)

51 (10.3%)

High school or associate’s 294 (41.5%)

244 (49.3%)

Bachelor’s or graduate

292 (41.2%)

138 (27.9%)

Unknown

83 (11.7%)

62 (12.5%)

Statistical tests exclude missing or unknown values.
Chi-squared test of no association.
b
Wilcoxon rank-sum test.
a
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Table 2 Unadjusted Analyses of Reported Family History
of Autoimmune Disease

Table 3 Adjusted Analyses of Reported Family History of
Autoimmune Disease
OR (95% CI)

p Value

Any reported family historya

2.27 (1.71, 3.01)

<0.001

Subject status as case or
control

Any reported family historya
Diabetes: adult onset

Control
(N = 709)

Case
(N = 495)

p Value

Diabetes: adult onset

1.80 (1.37, 2.35)

<0.001

351 (49.5%)

337 (68.1%)

<0.001b

Diabetes: childhood onset

2.26 (1.22, 4.22)

0.010

221 (44.6%)

b

Thyroid disease/Hashimoto disease/
Graves disease

1.72 (1.22, 2.43)

0.002

Rheumatoid arthritis

1.63 (1.11, 2.38)

0.012

4.16 (2.57, 6.75)

<0.001

Atopic dermatitis/eczema

0.89 (0.52, 1.51)

0.656

Psoriasis

1.08 (0.63, 1.84)

0.792

Inflammatory bowel disease/Crohn
disease/ulcerative colitis

1.95 (1.09, 3.47)

0.024

Systemic lupus erythematosus

2.16 (1.16, 4.01)

0.015

Other autoimmune disease

1.35 (0.92, 1.99)

0.129

211 (29.8%)

<0.001

b

Diabetes: childhood onset

19 (2.7%)

31 (6.3%)

0.002

Thyroid disease/Hashimoto
disease/Graves disease

95 (13.4%)

99 (20.0%)

0.002b

Rheumatoid arthritis
MS

a

MS
66 (9.3%)

77 (15.6%)

b

<0.001

b

29 (4.1%)

68 (13.7%)

45 (6.3%)

24 (4.8%)

0.271b

36 (5.1%)

26 (5.3%)

0.892

b

Inflammatory bowel disease/
25 (3.5%)
Crohn disease/ulcerative colitis

29 (5.9%)

0.054b

Systemic lupus erythematosus

22 (3.1%)

28 (5.7%)

0.029b

Other autoimmune disease

72 (10.2%)

69 (13.9%)

0.045b

Atopic dermatitis/eczema
Psoriasis

<0.001

Abbreviation: MS = multiple sclerosis.
Celiac disease, hyperparathyroidism, Sjogren syndrome, rheumatic heart
disease, sarcoidosis, idiopathic thrombocytopenic purpura, vitiligo, mixed
connective tissue disease, scleroderma, pernicious anemia, ankylosing
spondylitis, chronic inflammatory demyelinating polyneuropathy, GuillainBarre syndrome, myasthenia gravis, pemphigus vulgaris, vasculitis, Addison
disease, polymyositis, Bechet syndrome, and polyarteritis nodosa were
grouped with the other autoimmune disease category.
a
Excludes first-degree history of MS.
b
Chi-squared test of no association.

and paternal relatives. The same statistical methods applied to
the overall analyses were implemented in the relative group
analyses. When expected cell counts were less than 5, Fisher
exact tests were performed in place of χ 2 tests. A signiﬁcance
level of 0.05 was used for all analyses.
Data Availability
Deidentiﬁed data sets from this study can be made available to
qualiﬁed investigators with appropriate ethics/IRB approval.
Data are stored for up to 5 years postpublication.

Results
Participants’ Characteristics
This study included 1,204 participants with 709 controls and
495 cases (37 of which were categorized as clinically isolated
syndrome). The breakdown of cases and controls based on age,
sex, race, and ethnicity is summarized in Table 1. Groups were
well matched except for ethnicity and mother’s education.
Family History of Autoimmune Disorders
Because controls could not have a history of MS in immediate
biological family members (study exclusion criteria), analyses
Neurology.org/NN

a

Abbreviation: MS = multiple sclerosis.
Results are based on models adjusting for age, sex, race, ethnicity, and
biological mother’s highest level of education.
a
Excludes first-degree history of MS.

involving familial MS excluded ﬁrst-degree relatives. There was
a signiﬁcant diﬀerence in prevalence of a family history of autoimmune disease in patients with MS compared with controls
(68.1% vs 49.5%, p < 0.001) (Table 2). The conditions with
signiﬁcant diﬀerences in prevalence between cases and controls
were childhood-onset and adult-onset diabetes, thyroid disorders, rheumatoid arthritis, MS (in non–ﬁrst-degree relatives),
and systemic lupus erythematosus. Signiﬁcant diﬀerences between cases and controls were also found for the “other” category. Rates of eczema, psoriasis, and bowel disorders did not
diﬀer signiﬁcantly. With adjusted analyses (adjusted for age, sex,
race, ethnicity, and biological mother’s highest level of education), the OR of any family history of autoimmune disease was
2.27 among cases compared with controls (95% CI, 1.71–3.01,
p < 0.001) (Table 3). With adjusted analyses, the OR of any
family history of MS (in non–ﬁrst-degree relatives) was 4.16
among cases compared with controls (95% CI, 2.57–6.75, p <
0.001) (Table 3). Furthermore, with the adjusted analyses, the
other category of autoimmune diseases lost statistical signiﬁcance while inﬂammatory bowel diseases were more prevalent
in families of patients with pediatric MS (p = 0.024).
Separate analyses were performed to understand the association between family history of autoimmune diseases and
pediatric MS based on which relatives were reported as having
autoimmune diseases. The analysis was performed for several
categories of relatives: all ﬁrst-degree relatives, just parents,
second-degree relatives, maternal relatives, and paternal relatives. History of MS in pediatric MS patient’s mothers was
excluded from the maternal relative analysis for MS, and
history of MS in patient’s fathers was excluded from the
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Table 4 Analyses of Reported History of Autoimmune Disease Within Various Relative Groups

Control (N = 709)

Case (N = 495)

44 (6.2%)

48 (9.7%)

Unadjusted analyses

Adjusted analysesc

p Value

OR (95% CI)

p Value

0.025a

1.41 (0.88, 2.28)

0.156

0.038

a

1.80 (0.50, 6.50)

0.369

a

1.73 (1.10, 2.72)

0.018

First-degree relatives
Diabetes: adult onset
Diabetes: childhood onset

4 (0.6%)

9 (1.8%)

Thyroid disease/Hashimoto disease/Graves disease

47 (6.6%)

52 (10.5%)

0.016

Rheumatoid arthritis

9 (1.3%)

16 (3.2%)

0.019a

2.52 (1.04, 6.10)

0.040

a

1.49 (0.64, 3.47)

0.352

Inflammatory bowel disease/Crohn
disease/ulcerative colitis

12 (1.7%)

11 (2.2%)

0.509

Systemic lupus erythematosus

5 (0.7%)

7 (1.4%)

0.249b

2.58 (0.70, 9.52)

0.155

Other autoimmune disease

30 (4.2%)

26 (5.3%)

0.408a

1.14 (0.62, 2.07)

0.675

Diabetes: adult onset

144 (20.3%)

160 (32.3%)

<0.001a

1.88 (1.41, 2.51)

<0.001

Diabetes: childhood onset

6 (0.8%)

10 (2.0%)

0.080a

2.83 (0.92, 8.69)

0.070

Thyroid disease/Hashimoto disease/Graves disease

41 (5.8%)

31 (6.3%)

0.730a

1.06 (0.63, 1.80)

0.822

a

1.73 (1.07, 2.79)

0.024

Second-degree relatives

Rheumatoid arthritis

38 (5.4%)

45 (9.1%)

0.012

MS

8 (1.1%)

15 (3.0%)

0.018a

3.47 (1.36, 8.86)

0.009

Inflammatory bowel disease/Crohn disease/
ulcerative colitis

6 (0.8%)

10 (2.0%)

0.080a

2.39 (0.84, 6.86)

0.104

Systemic lupus erythematosus

8 (1.1%)

9 (1.8%)

0.318a

1.58 (0.58, 4.31)

0.373

Other autoimmune disease

30 (4.2%)

31 (6.3%)

0.114a

1.35 (0.78, 2.35)

0.290

44 (6.2%)

48 (9.7%)

0.025a

1.41 (0.88, 2.28)

0.156

Parents
Diabetes: adult onset

-

-d

0.088a

1.49 (0.93, 2.37)

0.096

15 (3.0%)

0.031a

2.34 (0.95, 5.75)

0.063

a

2.01 (0.77, 5.24)

0.152

Diabetes: childhood onset

0 (0.0%)

2 (0.4%)

0.169

Thyroid disease/Hashimoto disease/Graves
disease

47 (6.6%)

46 (9.3%)

Rheumatoid Arthritis

9 (1.3%)

b

d

Inflammatory bowel disease/Crohn disease/
ulcerative colitis

8 (1.1%)

10 (2.0%)

0.210

Systemic lupus erythematosus

5 (0.7%)

5 (1.0%)

0.749b

1.77 (0.43, 7.32)

0.430

a

1.14 (0.61, 2.14)

0.688

<0.001a

Other autoimmune disease

27 (3.8%)

24 (4.8%)

132 (18.6%)

138 (27.9%)

0.378

Maternal relatives
Diabetes: adult onset
Diabetes: childhood onset

2 (0.3%)

10 (2.0%)

1.61 (1.19, 2.17)

0.002

0.005

b

8.71 (1.87, 40.43)

0.006

a

1.53 (1.05, 2.21)

0.025

Thyroid disease/Hashimoto disease/Graves disease

80 (11.3%)

76 (15.4%)

0.039

Rheumatoid arthritis

45 (6.3%)

51 (10.3%)

0.013a

1.51 (0.97, 2.36)

0.068

MSa

20 (2.8%)

32 (6.5%)

0.002a

2.64 (1.43, 4.89)

0.002

a

1.83 (0.82, 4.07)

0.137

Inflammatory bowel disease/Crohn disease/
ulcerative colitis

12 (1.7%)

14 (2.8%)

0.182

Systemic lupus erythematosus

15 (2.1%)

16 (3.2%)

0.229a

1.97 (0.92, 4.26)

0.083

Other autoimmune disease

49 (6.9%)

50 (10.1%)

0.047a

1.32 (0.84, 2.09)

0.230
Continued
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Table 4 Analyses of Reported History of Autoimmune Disease Within Various Relative Groups (continued)
Unadjusted analyses

Adjusted analysesc

Control (N = 709)

Case (N = 495)

p Value

OR (95% CI)

p Value

Diabetes: adult onset

86 (12.1%)

104 (21.0%)

<0.001a

1.87 (1.33, 2.63)

<0.001

Diabetes: childhood onset

6 (0.8%)

11 (2.2%)

0.046a

2.88 (1.04, 7.97)

0.042

Thyroid disease/Hashimoto disease/Graves disease

17 (2.4%)

20 (4.0%)

0.104a

1.80 (0.90, 3.63)

0.098

26 (5.3%)

0.003

a

2.92 (1.44, 5.91)

0.003

<0.001

a

6.37 (2.97, 13.66)

<0.001

Paternal relatives

Rheumatoid arthritis
MS

15 (2.1%)

e

9 (1.3%)

35 (7.1%)

Inflammatory bowel disease/Crohn disease/
ulcerative colitis

7 (1.0%)

13 (2.6%)

0.029a

3.60 (1.32, 9.84)

0.012

Systemic lupus erythematosus

5 (0.7%)

8 (1.6%)

0.132a

2.42 (0.75, 7.85)

0.140

a

1.33 (0.66, 2.69)

0.425

Other autoimmune disease

20 (2.8%)

19 (3.8%)

0.326

Abbreviation: MS = multiple sclerosis.
a
Chi-squared test of no association.
b
Fisher exact test.
c
Adjusted analyses are based on logistic models adjusting for age, sex, race, ethnicity, and biological mother’s highest level of education.
d
The logistic regression model for childhood-onset diabetes reported in subject’s parents was not stable as none of the controls reported parents with
childhood-onset diabetes.
a
Excludes history of MS in mothers as controls with first-degree history of MS are excluded from the study.
e
Excludes history of MS in fathers as controls with first-degree history of MS are excluded from the study.

paternal relative analysis for MS, as controls could not have a
history of MS in either parent. Adjusted analyses revealed an
OR of 3.47 of MS among second-degree relatives of patients
with pediatric MS. The OR was 2.64 when restricted to maternal relatives and 6.37 when restricted to paternal relatives
(Table 4). Adjusted analyses revealed that there was a statistically signiﬁcant diﬀerence between cases and controls in
prevalence of adult-onset diabetes, childhood-onset diabetes,
and MS in both maternal and paternal secondary relatives.
Rheumatoid arthritis and inﬂammatory bowel disease had a
higher prevalence in paternal second-degree relatives, but not
maternal. In contrast, thyroid disorders had a higher prevalence in maternal second-degree relatives, but not paternal.

4.1% of controls (for whom parents could not have the disease
as speciﬁed by study exclusion criteria). In another study,
25.5% of patients with adult MS reported a family history of
MS compared with only 4.1% of controls.14 There were signiﬁcant diﬀerences between cases and controls relative to the
frequency of autoimmune diseases (e.g., diabetes and rheumatoid arthritis), suggesting some shared risk factors for these
conditions. Indeed, prior work has suggested shared genetic
variants across several autoimmune disorders.15

Discussion

Presumably, the link between various autoimmune diseases
might be genetic and/or environmental exposures that trigger
an aberrant immune response. Although various autoimmune
diseases diﬀer in their target organs and antigens, they share a
common loss of self-tolerance. When analyzing the rate of
familial autoimmune diseases, especially among non–ﬁrstdegree relatives, an increased risk of autoimmune conditions
would likely be caused by shared genetic risk factors, rather
than environmental exposures. Understanding families with
increased rates of autoimmune conditions could provide an
opportunity for dissecting out the universal genetic risks for
autoimmunity separate from the genetic risk factors associated with single conditions. This study found that there was a
higher rate of MS in second-degree relatives among the patients with pediatric MS compared with controls, and this
diﬀerence was most pronounced when the history of MS was

We sought to identify the prevalence of familial autoimmune
disorders in pediatric MS compared with controls as most
studies have focused on adult MS.12 As children who develop
MS 20–30 years earlier than average age at onset likely have
larger genetic burden and/or environmental exposures than
adults with the disease, the prevalence of autoimmune disorders in their family may be higher than reported for adults
with MS. Studies of a familial history of autoimmune disease
in patients with adult MS have yielded conﬂicting results.14,15
We have identiﬁed a number of autoimmune conditions with
increased prevalence among the family members of patients
with pediatric MS. Of note, 13.7% of patients with pediatric
MS reported a familial history of MS compared with only
Neurology.org/NN

Notably, not all autoimmune conditions followed this pattern.
There was no increase in the odds of psoriasis and eczema
among family members of pediatric MS cases compared with
controls.
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paternal. Risk of various autoimmune diseases based on parent of origin has been described in numerous genetics studies,
with some conditions having maternal associations (e.g.,
Crohn and juvenile idiopathic arthritis) and others having
paternal associations (e.g., psoriatic arthritis).16,17
Strengths of the study include the prospective collection of data
in multiple centers in the United States representing various
geographical areas, careful case ascertainment, and the number
of pediatric patients recruited. In addition, controls were enrolled at the same institutions than cases. Weaknesses include
the survey-based format of data collection (i.e., the lack of
medical conﬁrmation of autoimmune disorders reported by
families) and the potential for a biased sampling of controls
since recruitment occurred at academic pediatric hospitals and
clinics. There are risks for both under- and over-reporting of
family history and the possibility of recall bias among cases.
Although recall bias could deﬁnitely lead to an overestimation
of autoimmune diseases in the case cohort, the fact that several
conditions were found to have no statistical diﬀerence between
cases and control reduces the bias concern.
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The higher rate of autoimmune diseases among family
members of patients with pediatric MS compared with controls, especially the higher rate of MS in second-degree relatives among the patients with pediatric MS, supports the
possibility of shared genetic variants between several autoimmune diseases and MS. The higher rate of speciﬁc disorders
among paternal relatives raises the question of possible imprinting. The rate of autoimmune disease in this control cohort was higher than the general population, particularly in
terms of the percent of participants reporting adult onset
diabetes within their family (i.e., 29%). This represents a
potential bias to the conclusions that could skew the signiﬁcance of the ﬁndings, but not likely change the overall conclusion. Future studies could be designed to compare the
genetic proﬁles of various pediatric autoimmune disorders in
an attempt to determine disease speciﬁc genes separate from
the genes that dictate risk of losing self-tolerance. Combining
cohort and family history diagnostic data with expanded
genotyping could help establish relative risk of autoimmunity
in families based on genetic predispositions. This would require expanded genotyping programs beyond traditional trio
designed genetic studies.
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